|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
|
US4740461A
(en)
|
1983-12-27 |
1988-04-26 |
Genetics Institute, Inc. |
Vectors and methods for transformation of eucaryotic cells
|
|
US4959455A
(en)
|
1986-07-14 |
1990-09-25 |
Genetics Institute, Inc. |
Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
WO1988001649A1
(en)
|
1986-09-02 |
1988-03-10 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
|
US5011912A
(en)
|
1986-12-19 |
1991-04-30 |
Immunex Corporation |
Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
|
|
US4965195A
(en)
|
1987-10-26 |
1990-10-23 |
Immunex Corp. |
Interleukin-7
|
|
US4968607A
(en)
|
1987-11-25 |
1990-11-06 |
Immunex Corporation |
Interleukin-1 receptors
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
AU643427B2
(en)
|
1988-10-31 |
1993-11-18 |
Immunex Corporation |
Interleukin-4 receptors
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5683888A
(en)
|
1989-07-22 |
1997-11-04 |
University Of Wales College Of Medicine |
Modified bioluminescent proteins and their use
|
|
US5292658A
(en)
|
1989-12-29 |
1994-03-08 |
University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center |
Cloning and expressions of Renilla luciferase
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
ES2087997T3
(es)
|
1990-01-12 |
1996-08-01 |
Cell Genesys Inc |
Generacion de anticuerpos xenogenicos.
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
AU651596B2
(en)
|
1990-06-05 |
1994-07-28 |
Immunex Corporation |
Type II interleukin-1 receptors
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
JP3126980B2
(ja)
|
1991-03-11 |
2001-01-22 |
ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド |
レニラ（ｒｅｎｉｌｌａ）ルシフェラーゼのクローニング及び発現
|
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
|
CA2111348A1
(en)
|
1991-06-14 |
1992-12-23 |
John S. Logan |
Production of human hemoglobin in transgenic pigs
|
|
JPH06508880A
(ja)
|
1991-07-08 |
1994-10-06 |
ユニバーシティ オブ マサチューセッツ アット アムハースト |
サーモトロピック液晶セグメント化ブロックコポリマー
|
|
US5470582A
(en)
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
|
JPH07509137A
(ja)
|
1992-07-24 |
1995-10-12 |
セル ジェネシス，インク． |
異種抗体の生産
|
|
AU694745B2
(en)
|
1993-09-10 |
1998-07-30 |
Trustees Of Columbia University In The City Of New York, The |
Uses of green fluorescent protein
|
|
WO1995021191A1
(en)
|
1994-02-04 |
1995-08-10 |
William Ward |
Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
|
|
US5777079A
(en)
|
1994-11-10 |
1998-07-07 |
The Regents Of The University Of California |
Modified green fluorescent proteins
|
|
EP0822830B1
(en)
|
1995-04-27 |
2008-04-02 |
Amgen Fremont Inc. |
Human anti-IL-8 antibodies, derived from immunized xenomice
|
|
US5874304A
(en)
|
1996-01-18 |
1999-02-23 |
University Of Florida Research Foundation, Inc. |
Humanized green fluorescent protein genes and methods
|
|
US5804387A
(en)
|
1996-02-01 |
1998-09-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
FACS-optimized mutants of the green fluorescent protein (GFP)
|
|
US5876995A
(en)
|
1996-02-06 |
1999-03-02 |
Bryan; Bruce |
Bioluminescent novelty items
|
|
US5925558A
(en)
|
1996-07-16 |
1999-07-20 |
The Regents Of The University Of California |
Assays for protein kinases using fluorescent protein substrates
|
|
ES2359031T3
(es)
|
1996-08-08 |
2011-05-17 |
Amylin Pharmaceuticals, Inc. |
Composición farmacéutica que comprende un péptido de exendina-4.
|
|
US5976796A
(en)
|
1996-10-04 |
1999-11-02 |
Loma Linda University |
Construction and expression of renilla luciferase and green fluorescent protein fusion genes
|
|
EP2305027B1
(en)
|
1996-12-03 |
2014-07-02 |
Amgen Fremont Inc. |
Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
|
|
US7091183B1
(en)
|
1996-12-03 |
2006-08-15 |
Boston Medical Center Corporation |
Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
|
|
AU5518798A
(en)
|
1996-12-03 |
1998-06-29 |
Trustees Of Boston University |
Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
|
|
US6458547B1
(en)
|
1996-12-12 |
2002-10-01 |
Prolume, Ltd. |
Apparatus and method for detecting and identifying infectious agents
|
|
JP4798814B2
(ja)
|
1997-01-07 |
2011-10-19 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
食物摂取低減用のエキセンジンおよびそのアゴニストの使用
|
|
CA2196496A1
(en)
|
1997-01-31 |
1998-07-31 |
Stephen William Watson Michnick |
Protein fragment complementation assay for the detection of protein-protein interactions
|
|
US6753165B1
(en)
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
DK1019077T4
(da)
|
1997-08-08 |
2011-03-07 |
Amylin Pharmaceuticals Inc |
Hidtil ukendte exendinagonistforbindelser
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
AU756836B2
(en)
|
1997-11-14 |
2003-01-23 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
WO1999025727A2
(en)
|
1997-11-14 |
1999-05-27 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
ATE366115T1
(de)
|
1998-02-13 |
2007-07-15 |
Amylin Pharmaceuticals Inc |
Inotropische und diuretische effekte von exendin und glp-1
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
EP1064360B1
(en)
|
1998-03-27 |
2008-03-05 |
Prolume, Ltd. |
Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
|
|
AU6294899A
(en)
|
1998-10-07 |
2000-04-26 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
|
PL205713B1
(pl)
|
1998-12-07 |
2010-05-31 |
Sod Conseils Rech Applic |
Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
|
|
CA2358107C
(en)
|
1998-12-22 |
2011-08-23 |
Eli Lilly And Company |
Shelf-stable formulation of glucagon-like peptide-1
|
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
DE60032331T2
(de)
|
1999-01-14 |
2007-06-21 |
Amylin Pharmaceuticals, Inc., San Diego |
Exendine zur glucagon suppression
|
|
EP1140145B2
(en)
|
1999-01-14 |
2019-05-15 |
Amylin Pharmaceuticals, LLC |
Novel exendin agonist formulations and methods of administration thereof
|
|
US6921748B1
(en)
|
1999-03-29 |
2005-07-26 |
Uutech Limited |
Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes
|
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
CA2385888A1
(en)
|
1999-09-27 |
2001-04-05 |
The Regents Of The University Of California |
Engineering antibodies that bind irreversibly
|
|
JP2003519667A
(ja)
|
2000-01-10 |
2003-06-24 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
トリグリセリドレベルの調節および脂質異常血症の治療のためのエキセンジンおよびそのアゴニストの使用
|
|
BR0107837A
(pt)
|
2000-01-27 |
2003-01-14 |
Lilly Co Eli |
Processo para solubilização de compostos peptìdeo 1 semelhantes a glucagon
|
|
US20030157107A1
(en)
|
2000-05-16 |
2003-08-21 |
Kazumasa Miyawaki |
Agents for preventing or ameliorating insulin resistance and/or obesity
|
|
DK2322631T3
(en)
|
2001-04-19 |
2015-01-12 |
Scripps Research Inst |
Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
|
|
US20050159379A1
(en)
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
|
JP4566459B2
(ja)
|
2001-06-07 |
2010-10-20 |
株式会社日立製作所 |
表示装置
|
|
AU2002358469A1
(en)
|
2001-12-21 |
2003-07-15 |
7Tm Pharma A/S |
Modified receptors for the discovery of therapeutic ligands
|
|
CN1332711C
(zh)
|
2002-02-20 |
2007-08-22 |
埃米球科技有限公司 |
施用glp－1分子的方法
|
|
EP1506777A4
(en)
|
2002-05-22 |
2007-07-18 |
Sanwa Kagaku Kenkyusho Co |
MEANS FOR PREVENTING OR REDUCING FAT SUPPORT WITH A METHYLIDENHYDRAZIDE COMPOUND AS AN ACTIVE SUBSTANCE
|
|
US20040029805A1
(en)
|
2002-06-15 |
2004-02-12 |
Wolfe M. Michael |
Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP)
|
|
JP2006213598A
(ja)
|
2003-03-19 |
2006-08-17 |
Sanwa Kagaku Kenkyusho Co Ltd |
ピラゾロピリミジン化合物及びその用途
|
|
EA008831B1
(ru)
|
2003-06-12 |
2007-08-31 |
Эли Лилли Энд Компани |
Слитые белки аналогов glp-1
|
|
WO2005021022A2
(en)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
BRPI0507594A
(pt)
|
2004-02-11 |
2007-07-03 |
Amylin Pharmaceuticals Inc |
polipetìdeos hìbridos com propriedades selecionáveis
|
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
US7991890B2
(en)
|
2004-09-30 |
2011-08-02 |
Microsoft Corporation |
Game console communication with a device
|
|
WO2006045796A2
(en)
|
2004-10-25 |
2006-05-04 |
Cytos Biotechnology Ag |
Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
|
|
BRPI0519393A2
(pt)
|
2004-12-22 |
2009-01-20 |
Lilly Co Eli |
formulaÇço em soluÇço estÁvel
|
|
US20060275288A1
(en)
|
2005-01-20 |
2006-12-07 |
Grihalde Nelson D |
GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
|
|
EP1853627A2
(en)
|
2005-02-11 |
2007-11-14 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
EP1882044A1
(en)
|
2005-05-11 |
2008-01-30 |
sanofi-aventis |
Use of a gip promoter polymorphism
|
|
EP1888118B1
(en)
|
2005-05-25 |
2016-08-17 |
Novo Nordisk A/S |
Polypeptide formulations stabilized with ethylenediamine
|
|
EP1943274A2
(en)
*
|
2005-09-08 |
2008-07-16 |
Uutech Limited |
Treatment of diabetes related obesity
|
|
CN101432025B
(zh)
|
2006-03-21 |
2012-04-04 |
安米林药品公司 |
肽-肽酶抑制剂结合物及其使用方法
|
|
EP2015776A1
(en)
|
2006-04-20 |
2009-01-21 |
Amgen Inc. |
Glp-1 compound/glucagon antibody compositions
|
|
MX2008013304A
(es)
|
2006-04-20 |
2008-10-27 |
Amgen Inc |
Compuestos de peptido 1 tipo glucagon.
|
|
CA2657103A1
(en)
|
2006-07-07 |
2008-01-10 |
The Texas A&M University System |
Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis
|
|
WO2008019143A2
(en)
|
2006-08-04 |
2008-02-14 |
Amylin Pharmaceuticals, Inc |
Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
WO2008021560A2
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable properties
|
|
US20090098130A1
(en)
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
JP6017754B2
(ja)
|
2007-02-15 |
2016-11-02 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
グルカゴン／ｇｌｐ−１受容体コアゴニスト
|
|
WO2009042922A2
(en)
|
2007-09-27 |
2009-04-02 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of making and using same
|
|
US20090144162A1
(en)
|
2007-11-29 |
2009-06-04 |
Neil Milne |
Transaction Security Method and Apparatus
|
|
GB0814068D0
(en)
|
2008-08-01 |
2008-09-10 |
Univ Ulster |
Active immunisation against GIP
|
|
KR20130133104A
(ko)
|
2008-08-07 |
2013-12-05 |
입센 파마 에스.에이.에스 |
포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
|
|
EP2328922A4
(en)
|
2008-08-07 |
2013-01-02 |
Ipsen Pharma Sas |
ANALOGUE OF GLUCOSE-DEPENDING INSULINOTROPIC POLYPEPTIDE
|
|
CA2733005C
(en)
|
2008-08-07 |
2016-09-27 |
Ipsen Pharma S.A.S. |
Truncated analogues of glucose-dependent insulinotropic polypeptide
|
|
WO2010016936A1
(en)
|
2008-08-07 |
2010-02-11 |
Ipsen Pharma S.A.S. |
Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
|
|
BRPI0917580A2
(pt)
|
2008-08-07 |
2016-10-11 |
Ipsen Pharma Sas |
composto, composição farmacêutica, métodos para elicitar um efeito agonista e antagonista de um receptor de gip, para tratar condições ou doenças mediadas por ligação de receptor de gip, para tratar diabetes, para tratar distúrbios relacionados com diabete, para tratar ou previnir causas secundárias de diabete para tratar obesidade, e para estimular secreção de insulina, e, uso de um análogo de peptídeo
|
|
US20120157379A1
(en)
|
2009-07-31 |
2012-06-21 |
Sheau Yu Hsu |
Gastric Inhibitory Peptide Variants and Their Uses
|
|
RU2012136450A
(ru)
|
2010-01-27 |
2014-03-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
|
|
US9023986B2
(en)
|
2010-10-25 |
2015-05-05 |
Hoffmann-La Roche Inc. |
Glucose-dependent insulinotropic peptide analogs
|
|
CA2821766A1
(en)
|
2010-12-22 |
2012-06-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
|
JP5977733B2
(ja)
|
2011-03-08 |
2016-08-24 |
株式会社三和化学研究所 |
分析方法
|
|
WO2012167744A1
(en)
|
2011-06-10 |
2012-12-13 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
|
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
|
US9745359B2
(en)
|
2012-05-18 |
2017-08-29 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
|
AU2013311777B2
(en)
|
2012-09-07 |
2018-02-01 |
Sanofi |
Fusion proteins for treating a metabolic syndrome
|
|
WO2014100913A1
(en)
|
2012-12-24 |
2014-07-03 |
Beijing Anxinhuaide Biotech. Co., Ltd |
Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
|
|
CN104371019B
(zh)
|
2013-08-13 |
2019-09-10 |
鸿运华宁（杭州）生物医药有限公司 |
一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
|
|
WO2015022420A1
(en)
|
2013-08-16 |
2015-02-19 |
Medimmune Limited |
Gip and glp-1 receptor dual-agonists for the treatment of diabetes
|
|
US20160297883A1
(en)
*
|
2013-12-04 |
2016-10-13 |
Innovative Targeting Solutions, Inc. |
G-protein coupled receptor agonists and methods
|
|
US11219690B2
(en)
|
2013-12-13 |
2022-01-11 |
Novo Nordisk Healthcare Ag |
Method for thioether conjugation of proteins
|
|
CN113633768B
(zh)
|
2013-12-17 |
2025-11-11 |
Mhs克尔创新有限责任公司 |
治疗脂肪组织积聚的组合物和方法
|
|
WO2015157595A1
(en)
|
2014-04-11 |
2015-10-15 |
Medimmune, Llc |
Conjugated compounds comprising cysteine-engineered antibodies
|
|
EP3151852A1
(en)
|
2014-06-04 |
2017-04-12 |
Novo Nordisk A/S |
Glp-1/glucagon receptor co-agonists for medical use
|
|
US10077318B2
(en)
|
2014-09-12 |
2018-09-18 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
US10097078B2
(en)
|
2014-10-21 |
2018-10-09 |
Toshiba International Corporation |
Multi-mode energy router
|
|
KR101825048B1
(ko)
*
|
2014-12-31 |
2018-02-05 |
주식회사 제넥신 |
GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
|
|
TWI669309B
(zh)
|
2015-06-22 |
2019-08-21 |
美商美國禮來大藥廠 |
升糖素及ｇｌｐ－１共激動劑化合物
|
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
|
SG11201805255TA
(en)
|
2015-12-23 |
2018-07-30 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
|
US20180237095A1
(en)
|
2017-02-23 |
2018-08-23 |
Motive Power Industry Co., Ltd. |
Two-wheel suspension mechanism
|
|
AU2018288854B2
(en)
|
2017-06-20 |
2025-06-26 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
|
|
CA3263567A1
(en)
|
2017-06-21 |
2025-10-30 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
|
|
MA68842B1
(fr)
|
2017-08-04 |
2025-01-31 |
Amgen Inc. |
Procédé de conjugaison de cys-mabs
|